Program
Prednisone
Also written as “prednisone”, “CHOP” and “Lodotra®”.
Its studies are mostly in Prostatic Neoplasms · Lymphoma, Large B-Cell, Diffuse · Arthritis, Rheumatoid · Lymphoma, T-Cell, Peripheral · Asthma, led by 13 companies.
Drug pagePrednisone: every studyMany companies study it; this page follows only the 26 they lead. All 547 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 40 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Sanofiits history only | 40 open or running | phase 4since Jul 20, 2012 | Mar 3, 2011 | none ahead |
| Bristol-Myers Squibbits history only | 30 open or running | phase 2since Apr 19, 2007 | Apr 19, 2007 | none ahead |
| Takedaits history only | 31 open or running | phase 3since Jul 25, 2007 | Jul 25, 2007 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 4since Jul 8, 2014 | Jul 8, 2014 | none ahead |
| Eli Lillyits history only | 21 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Mundipharmaits history only | 20 open or running | phase 4since Feb 14, 2014 | Mar 14, 2013 | none ahead |
| Amgenits history only | 10 open or running | phase 2since May 26, 2008 | May 26, 2008 | none ahead |
| Ampel BioSolutionsits history only | 10 open or running | phase 4since Mar 21, 2017 | Mar 21, 2017 | none ahead |
| CareDx | 11 open or running | no phasesince Oct 21, 2026 | Oct 21, 2026 | Dec 2028NCT07905599 |
| Ionis Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 2, 2010 | Nov 2, 2010 | none ahead |
| Oncotherapeuticsits history only | 10 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
Also a collaborator on its studies: AbbVie, Basilea Pharmaceutica International and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CareDx only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 21, 2026First study: no phase study in Heart Transplant RejectionFirst studyNCT07905599 · 200 planned
Ahead
- Dec 2028Primary completion: no phase study in Heart Transplant RejectionNCT07905599
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The one study CareDx leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07905599Heart Transplant Rejection | – | Not yet recruiting | Dec 2028 | 200 |
How it is read
Names in the registry
- “Prednisone”, 39 entries
- “prednisone”, 7 entries
- “CHOP”, 2 entries
- “Lodotra®”, 2 entries
- “Abiraterone/prednisone”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 18 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Arthritis, Rheumatoid, 4 studies
- Lymphoma, T-Cell, Peripheral, 3 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.